Literature DB >> 8107209

Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins.

T C McGuire1, D B Tumas, K M Byrne, M T Hines, S R Leib, A L Brassfield, K I O'Rourke, L E Perryman.   

Abstract

Cytotoxic T lymphocytes (CTL) can control some viral infections and may be important in the control of lentiviruses, including human immunodeficiency virus type 1. Since there is limited evidence for an in vivo role of CTL in control of lentiviruses, dissection of immune mechanisms in animal lentiviral infections may provide needed information. Horses infected with equine infectious anemia virus (EIAV) a lentivirus, have acute plasma viremia which is terminated in immunocompetent horses. Viremic episodes may recur, but most horses ultimately control infection and become asymptomatic carriers. To begin dissection of the immune mechanisms involved in EIAV control, peripheral blood mononuclear cells (PBMC) from infected horses were evaluated for CTL to EIAV-infected cells. By using noninfected and EIAV-infected autologous equine kidney (EK) cells in 51Cr-release assays, EIAV-specific cytotoxic activity was detected in unstimulated PBMC from three infected horses. The EIAV-specific cytotoxic activity was major histocompatibility complex (MHC) restricted, as determined by assaying EIAV-infected heterologous EK targets, and was mediated by CD8+ T lymphocytes, as determined by depleting these cells by a panning procedure with an anti-CD8 monoclonal antibody. MHC-restricted CD8+ CTL in unstimulated PBMC from infected horses caused significant specific lysis of autologous EK cells infected with recombinant vaccinia viruses expressing EIAV genes, either env or gag plus 5' pol. The EIAV-specific MHC-restricted CD8+ CTL were detected in two EIAV-infected horses within a few days after plasma viremia occurred and were present after viremia was terminated. The detection of these immune effector cells in EIAV-infected horses permits further studies to determine their in vivo role.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8107209      PMCID: PMC236601     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Diagnosis of equine infectious anemia by immunodiffusion test.

Authors:  L Coggins; N L Norcross; S R Nusbaum
Journal:  Am J Vet Res       Date:  1972-01       Impact factor: 1.156

2.  Titration of equine infectious anemia virus. Effect of dosage on incubation time and clinical signs.

Authors:  L J Kemeny; L O Mott; J E Pearson
Journal:  Cornell Vet       Date:  1971-10

3.  Antigenic drift of equine infectious anemia virus in chronically infected horses.

Authors:  Y Kono; K Kobayashi; Y Fukunaga
Journal:  Arch Gesamte Virusforsch       Date:  1973

4.  Viremia and immunological responses in horses infected with equine infectious anemia virus.

Authors:  Y Kono
Journal:  Natl Inst Anim Health Q (Tokyo)       Date:  1969

5.  Isolation and comparative biochemical properties of the major internal polypeptides of equine infectious anemia virus.

Authors:  R C Montelaro; N Lohrey; B Parekh; E W Blakeney; C J Issel
Journal:  J Virol       Date:  1982-06       Impact factor: 5.103

6.  Virulence and in vitro growth of a cell-adapted strain of equine infectious anemia virus after serial passage in ponies.

Authors:  A Orrego; C J Issel; R C Montelaro; W V Adams
Journal:  Am J Vet Res       Date:  1982-09       Impact factor: 1.156

7.  Recrudescence of equine infectious anemia by treatment with immunosuppressive drugs.

Authors:  Y Kono; K Hirasawa; Y Fukunaga; T Taniguchi
Journal:  Natl Inst Anim Health Q (Tokyo)       Date:  1976

8.  Characterization of the infection of equine fibroblasts by equine infectious anemia virus.

Authors:  P Klevjer-Anderson; W P Cheevers; T B Crawford
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

9.  Leukocyte cytotoxicity in a persistent virus infection: presence of direct cytotoxicity but absence of antibody-dependent cellular cytotoxicity in horses infected with equine infectious anemia virus.

Authors:  Y Fujimiya; L E Perryman; T B Crawford
Journal:  Infect Immun       Date:  1979-06       Impact factor: 3.441

Review 10.  Scientific and social issues of human immunodeficiency virus vaccine development.

Authors:  B F Haynes
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

View more
  30 in total

1.  Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.

Authors:  S A Hammond; F Li; B M McKeon; S J Cook; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Subpopulations of equine infectious anemia virus Rev coexist in vivo and differ in phenotype.

Authors:  Prasith Baccam; Robert J Thompson; Yuxing Li; Wendy O Sparks; Michael Belshan; Karin S Dorman; Yvonne Wannemuehler; J Lindsay Oaks; James L Cornette; Susan Carpenter
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

3.  CTL from EIAV carrier horses with diverse MHC class I alleles recognize epitope clusters in Gag matrix and capsid proteins.

Authors:  Chungwon Chung; Robert H Mealey; Travis C McGuire
Journal:  Virology       Date:  2004-09-15       Impact factor: 3.616

4.  Selecting peptides to optimize Th1 responses to an equine lentivirus using HLA-DR binding motifs and defined HIV-1 Th peptides.

Authors:  Darrilyn G Fraser; Robert H Mealey; Travis C McGuire
Journal:  Immunogenetics       Date:  2003-08-27       Impact factor: 2.846

5.  Biological characterization of Rev variation in equine infectious anemia virus.

Authors:  M Belshan; M E Harris; A E Shoemaker; T J Hope; S Carpenter
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  Specific cytotoxic T lymphocytes are involved in in vivo clearance of infectious bronchitis virus.

Authors:  S H Seo; E W Collisson
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

7.  Lymphocyte proliferation responses induced to broadly reactive Th peptides did not protect against equine infectious anemia virus challenge.

Authors:  Darrilyn G Fraser; Steve R Leib; Bao Shan Zhang; Robert H Mealey; Wendy C Brown; Travis C McGuire
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

8.  Early development of cytotoxic T lymphocytes in neonatal foals following oral inoculation with Rhodococcus equi.

Authors:  Seth P Harris; Melissa T Hines; Robert H Mealey; Debra C Alperin; Stephen A Hines
Journal:  Vet Immunol Immunopathol       Date:  2011-03-21       Impact factor: 2.046

9.  Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.

Authors:  Hal P Bogerd; Rebecca L Tallmadge; J Lindsay Oaks; Susan Carpenter; Bryan R Cullen
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

10.  Cloning and large-scale expansion of epitope-specific equine cytotoxic T lymphocytes using an anti-equine CD3 monoclonal antibody and human recombinant IL-2.

Authors:  Robert H Mealey; Matt H Littke; Steven R Leib; William C Davis; Travis C McGuire
Journal:  Vet Immunol Immunopathol       Date:  2007-04-08       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.